NVAX
Novavax IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.46B
P/E Ratio
—
EPS
$-0.56
Beta
2.41
52W High
$11.97
52W Low
$6.13
50-Day MA
$8.95
200-Day MA
$8.43
Dividend Yield
—
Profit Margin
-14.70%
Forward P/E
2.58
PEG Ratio
1.32
About Novavax Inc
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $596.34M |
| Gross Profit (TTM) | $163.96M |
| EBITDA | $59.53M |
| Operating Margin | -7.19% |
| Return on Equity | -898.00% |
| Return on Assets | 1.99% |
| Revenue/Share (TTM) | $3.67 |
| Book Value | $-0.88 |
| Price-to-Book | 41.23 |
| Price-to-Sales (TTM) | 2.45 |
| EV/Revenue | 1.618 |
| EV/EBITDA | 1.72 |
| Quarterly Earnings Growth (YoY) | -38.10% |
| Quarterly Revenue Growth (YoY) | -79.10% |
| Shares Outstanding | $164.44M |
| Float | $141.47M |
| % Insiders | 5.01% |
| % Institutions | 69.55% |
Historical Volatility
HV 10-Day
66.62%
HV 20-Day
84.03%
HV 30-Day
87.71%
HV 60-Day
69.73%
HV Rank
90.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($14.11 target)
5
Buy1
Hold1
Sell2
Strong SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026